Compare Las Vegas Sands Corp. (LVS) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Las Vegas Sands Corp. vs Revvity Inc — how do they compare? Las Vegas Sands Corp. trades at $45.85 (market cap $30.36B), while Revvity Inc trades at $110.05 (market cap $11.87B). The key difference: Las Vegas Sands Corp. is far larger — about 2.6× Revvity Inc's market cap, and Las Vegas Sands Corp. pays the higher dividend (2.4%). Which is the better fit depends on your goals.
| LVS | RVTY | |
|---|---|---|
Market Cap | $30.36B | $11.87B |
Sector | Consumer Cyclical | Technology |
52-Week High | $69.49 | $117.75 |
52-Week Low | $44.78 | $82.26 |
Enterprise Value | $42.75B | $14.36B |
Dividend Yield | 2.4% | 0.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LVS trades at $45.66, up 0.66% on the day, with a bearish technical signal but strong fundamentals. Recent quarters show consistent earnings beats, with Q1 2026 EPS of $0.91 beating expectations. Revenue growth is robust, reaching $13.02B in 2025, and profitability metrics like a 49.59% gross margin and 94.53% ROE are impressive. The company maintains positive cash flow and recently paid a $0.30 dividend. Analyst sentiment is bullish with a $65.18 consensus price target, though technical indicators suggest near-term pressure.
The outlook for LVS is positive based on fundamental strength and analyst optimism, but risks include high debt levels and bearish technical trends. Investment opportunity lies in its earnings momentum and valuation upside, while investors should monitor debt management and market volatility. The stock's current price near support levels may present a entry point if fundamentals hold.
RVTY trades at $106.44, down 3.37% today, but maintains a bullish technical outlook with strong analyst support. The company has consistently beaten earnings estimates for three consecutive quarters, with Q2 2026 results expected on August 4, 2026. Recent developments include AI integration partnerships and FDA clearances, supporting growth in its diagnostics and life sciences segments. Valuation metrics show a P/E of 52.96 and P/S of 4.35, reflecting premium pricing for its growth prospects.
The stock presents a balanced opportunity with analyst consensus pointing to 4.7% upside to the $111.43 price target. Strong institutional ownership and zero sell ratings indicate confidence, though high valuation multiples and negative cash flow trends pose risks. Earnings momentum from recent beats and strategic AI expansions provide catalysts, but investors should monitor margin pressures and China market exposure highlighted in recent quarters.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
